Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 73 | ECE2021 | Next issue

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

Card image cap
The European Congress of Endocrinology provides a global platform for the international endocrine community to discuss the latest advances in the field.

Presented Eposters

Presented ePosters 1: Adrenal and Cardiovascular Endocrinology

ea0073pep1.1 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Salivary steroid and 11‑oxygenated androgen profiles in patients with congenital adrenal hyperplasia on various glucocorticoid replacement regimens

Auer Matthias , Nowotny Hanna , Quinkler Marcus , Bidlingmaier Martin , Hawley James M , Adaway Jo , Keevil Brian , Ross Richard , Porter John , Reisch Nicole

Context11-oxygenated C19 steroids have recently gained attention as markers of androgen control in congenital adrenal hyperplasia (CAH) due to 21hydroxylase deficiency (21OHD). However, they have not yet been systematically investigated in the context of different glucocorticoid (GC) replacement regimens and in particular not in patients receiving new modified-release formulations.MethodsCross-sectional singl...

ea0073pep1.2 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Tildacerfont for the treatment of patients with classic congenital adrenal hyperplasia: results from a 12-week phase 2 clinical trial in adults with classic CAH

Auchus Richard , Merke Deborah , Ivy-Joan Madu , Nakhle Samer , Sarafoglou Kyriakie , Huang Michael , Moriarty David , Barnes Chris , Newfield Ron

BackgroundCongenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder characterized by insufficient cortisol production resulting in excess adrenocorticotropic hormone (ACTH) and adrenal androgen production. Standard-of-care therapy with glucocorticoids (GC) is suboptimal due to the difficulty of balancing control of the ACTH-driven androgen excess against the serious long-term side effects associated...

ea0073pep1.3 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Rationale for a reduced dexamethasone dosis in prenatal CAH therapy based on pharmacokinetic modelling

Reisch Nicole , Stachanow Viktoria , Neumann Uta , Blankenstein Oliver , Fuhr Uwe , Huisinga Wilhelm , Michelet Robin , Kloft Charlotte

ContextPrenatal dexamethasone (Dex) therapy is used in female foetuses with congenital adrenal hyperplasia (CAH) to suppress adrenal androgen excess and prevent virilisation of the external genitalia. The prenatal dexamethasone dose of 20 µg/kg per day has been used for decades in prenatal CAH and is associated with risks for the treated mother and potentially for the unborn child. Despite the high medical need, no prospective, clinical studies had ...

ea0073pep1.4 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Adrenocortical oncocytoma in a patient with classic congenital adrenal hyperplasia

Baleanu Maria Cristina , Simona Andreea Găloiu , Popa Lavinia , Gherlan Iuliana , Dumitrascu Anda , Poiana Catalina

IntroductionOncocytic neoplasms arising in adrenal tissue are extremely rare with nearly 150 cases being reported in literature. They are mostly nonfunctioning benign tumors, incidentally discovered, but 20% of them demonstrate elements of malignancy and up to 30% appear to affect hormone production.Case reportA 35 years old female with primary amenorrhea, diagnosed with Congenital Adrenal Hyperplasia due to ...

ea0073pep1.5 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Modified-release hydrocortisone improves androgen excess and facilitates glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia: non-invasive monitoring in saliva and urine

Prete Alessandro , Baranowski Elizabeth S. , Lina Schiffer , Adaway Joanne E. , Hawley James M. , Keevil Brian G. , Porter John , Ross Richard J. , Arlt Wiebke

BackgroundStandard glucocorticoid (GC) therapy in classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD-CAH) is often inadequate in controlling adrenal androgen excess, leading to GC over-exposure and poor health outcomes. A novel modified-release formulation of hydrocortisone (MR-HC, Chronocort® Diurnal Ltd. UK) has been shown to improve circulating adrenal androgen excess in 21-OHD-CAH. We investigated whether saliva and ...

ea0073pep1.6 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

ARMC5 modifies cell redox state to regulate steroidogenesis and lipid metabolism in the adrenal cortex

Isadora Pontes Cavalcante , Rizk-Rabin Marthe , Perlemoine Karine , Ribes Christopher , Jerome Bertherat , Ragazzon Bruno

BackgroundARMC5 is a putative tumor suppressor gene that is frequently mutated in primary bilateral macronodular adrenal hyperplasia (PBMAH), a rare cause of Cushing’s syndrome. The function of ARMC5 is poorly known, aside the fact that it regulates cell apoptosis and adrenal steroidogenesis in by mechanisms still unknown. Tumor suppressor genes play an important role in oxidative stress.MethodsIn this s...

ea0073pep1.7 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Adverse events of mitotane treatment in patients with adrenocortical carcinoma

Altieri Barbara , Detomas Mario , Kimpel Otilia , Quinkler Marcus , Canu Letizia , Mannelli Massimo , Angelousi Anna , Kaltsas Gregory , Elhassan Yasir , Casa Silvia Della , De Martino Maria Cristina , Megerle Felix , Cristina Ronchi , Kroiss Matthias , Fassnacht Martin

BackgroundMitotane represents the first-line medical treatment in most patients with adrenocortical carcinoma (ACC). Although adverse effects (AEs) due to mitotane are known to be frequent and may limit treatment, few systematic data are available. Aim of the study was to evaluate the AEs in ACC patients treated with mitotane monotherapy.MethodsA retrospective multicenter study including 311 ACC patients (M:F...

ea0073pep1.8 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Adrenal insufficiency with chronic hyponatraemia and normal basal cortisol level: time to review the investigation of hyponatraemia

Kalyan Mansukhbhai Shekhda , Darda Maria , Bitat Syed , Rathore Ali , Ojewuyi Taofeek , Ahlquist James

Adrenal insufficiency is serious, life-threatening condition. Classical features include nausea, malaise, weight loss and hypotension. It is usually diagnosed at a late stage only when it presents as adrenal crisis. We report a patient with autoimmune adrenal insufficiency who presented with chronic hyponatremia and a repeatedly normal serum cortisol level. A 66-year-old female was referred to endocrinology with a 12-month history of hyponatraemia (Na 125–131 mmol/l). She...